Analysis suggests that the combination ‘AATATT’ is the least effective in lowering CSC activities (Fig 13B) and the IL-6 level (Fig 13C) while the ‘AAATTT’ scheme is the most effective in suppressing onset of CRCC. This evidence concerns the gene IL6 and chromophobe renal cell carcinoma.